Gastric Cancer GS-US-296-1080

April 11, 2017

Sponsor: Gilead Sciences

Number: GS-US-296-1080 

The primary objective of this study is to compare the efficacy of GS-5745 versus placebo in combination with modified Fluorouracil (5-FU), Leucovorin (LV), and Oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.

Who’s eligible:

  • Adults with histologically confirmed (tissue microscopically examined) adenocarcinoma of the stomach or gastroesophageal junction, that is inoperable.
  • Locally advanced (cancer which has spread from the site of the primary (original) tumor only to surrounding tissue).
  • Metastatic (the development of secondary malignant growths at a distance from a primary site of cancer) and not amenable to curative therapy. The patient must have adequate hematologic, liver, coagulation and kidney function. The disease must be evaluable per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 (Response Evaluation Criteria in Solid Tumors).
  • This study is for patients age 18 and older.

Available at: The Hospital of Central Connecticut- The Cancer Center of Central Connecticut.

Cancer Clinical Research Office